Abvc Biopharma (ABVC) Accumulated Expenses (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Accumulated Expenses came in at $4.2 million in Q1 2026, up 8.56% YoY from $3.8 million in Q1 2025, and little changed on a QoQ basis from $4.2 million in Q4 2025.
Abvc Biopharma (ABVC) Accumulated Expenses (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 15 years of Accumulated Expenses data on file, last reported at $4.2 million in Q1 2026.
- Quarterly Accumulated Expenses rose 8.56% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 8.56% YoY) and the FY2025 annual result came in at $4.2 million, up 18.58% from the prior year.
- Accumulated Expenses held at $4.2 million in Q1 2026, from $4.2 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $4.2 million in Q4 2025 to a low of $160914.0 in Q2 2025.
- A 5-year average of $3.0 million and a median of $3.5 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses surged 196.15% — and 2025, when it tumbled 95.57%.
- Tracing ABVC's Accumulated Expenses over 5 years: stood at $2.9 million in 2022, then grew by 21.95% to $3.5 million in 2023, then dropped by 1.1% to $3.5 million in 2024, then grew by 18.58% to $4.2 million in 2025, then dropped by 0.17% to $4.2 million in 2026.
- The last three Accumulated Expenses figures came in at $4.2 million (Q1 2026), $4.2 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.20 Mn |
| Mar 31, 2026 | 4.15 Mn |
| Dec 31, 2025 | 4.16 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 160,914.00 |
| Mar 31, 2025 | 3.83 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 3.55 Mn |
| Sep 30, 2023 | 3.56 Mn |
| Jun 30, 2023 | 3.44 Mn |
| Mar 31, 2023 | 2.76 Mn |
| Dec 31, 2022 | 2.91 Mn |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 1.25 Mn |
| Mar 31, 2022 | 1.25 Mn |
| Dec 31, 2021 | 1.30 Mn |
| Sep 30, 2021 | 1.13 Mn |